Lilly (Eli) reported $79.7B of revenue over the trailing twelve months, +50% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $79.7B (to Q2 2026). Net income: $26.7B, trailing twelve months to Q2 2026. Free cash flow: $18.2B, trailing twelve months to Q2 2026. EPS: $29.80, trailing twelve months to Q2 2026.

LLYLilly (Eli)

Healthcare

$1,178.51+55% 1Y

$1,178.51

$711.1352 weeks$1.3K

LLY as reported

Lilly (Eli) reported $79.7B of revenue over the trailing twelve months, +50% on the year before. 11 reported series are charted on this page, each one as filed.

$79.7B

Revenue, trailing twelve months · to Q2 2026 · +50% against the twelve months before

Net income: $26.7B
Net income · +94% year on year · trailing twelve months to Q2 2026
Free cash flow: $18.2B
Free cash flow · +272% year on year · trailing twelve months to Q2 2026
EPS: $29.80
EPS · +95% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for LLY, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$79.7B	+50%	Q2 2026
Net income	$26.7B	+94%	Q2 2026
EPS	$29.80	+95%	Q2 2026
Gross margin	83%	n/a	Q2 2026
Operating margin	26%	n/a	Q4 2019 · 26 quarters behind
Net margin	34%	n/a	Q2 2026
ROE	79%	n/a	Q2 2026
ROA	19%	n/a	Q2 2026
ROIC	27%	n/a	Q4 2019 · 26 quarters behind
Free cash flow	$18.2B	+272%	Q2 2026
P/E	39.5	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.